NCT00254436View on ClinicalTrials.gov

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

PHASE3TerminatedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

June 29, 2004

Study Completion Date

June 29, 2004

Conditions

Gastrointestinal CancerRectal Cancer

Interventions

DRUG

Procrit (epoetin alfa)

Weekly dose

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Ortho Pharmaceuticals

All Listed Sponsors

collaborator

Ortho Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER